Quantifying the prevalence and determinants of respiratory syncytial virus (RSV) vaccine hesitancy in US adults aged 60 or older
Public Health · 2025
DOI: 10.1016/j.puhe.2024.08.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Public Health, 2025. Verfasst von M Motta und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Law, Policy, & Management, Boston University School of Public Health. Electronic address: mmotta@bu.edu. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Vaccines, Vaccination Hesitancy, Respiratory Syncytial Virus Infections. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 6 Literaturangaben. Gefördert von: State of Rhode Island Department of Health.
Abstract (Originalsprache)
OBJECTIVE: Federal regulators recently authorised two vaccines designed to prevent infection with respiratory syncytial virus (RSV) for adults aged 60 or older. While some efforts have been made to study vaccine uptake thus far, few have studied this group's intentions to vaccinate, as well as potential barriers to vaccination. This omission is noteworthy as adults aged 60 or older may be at an increased risk of experiencing severe complications from RSV infection. STUDY DESIGN & METHODS: We fielded a nationally representative survey of 1200 US adults (n = 362 aged 60+). Respondents aged 60 or older were asked a series of questions about their willingness to receive an RSV vaccine, vaccine safety, and efficacy attitudes, and their knowledge about vaccination eligibility. RESULTS: We find that a majority of seniors (53%) intend to refuse an RSV vaccine. As of late fall 2023, just 14% of those eligible had already received an RSV vaccine. Multivariate regression models suggest that belief in the safety and efficacy of the RSV vaccine, as well as previous flu and COVID-19 vaccine uptake, are associated with increased RSV vaccination intentions. CONCLUSIONS: We document high levels of RSV vaccine hesitancy among adults aged 60 or older and show that negative vaccine attitudes and non-vaccination behaviors motivate RSV vaccine refusal. Our work thereby raises the possibility that efforts to communicate the safety and efficacy of RSV vaccination may have beneficial effects on RSV vaccine uptake.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Law, Policy, & Management, Boston University School of Public Health. Electronic address: mmotta@bu.edu.
- Department of Health Law, Policy, & Management, Boston University School of Public Health.
- Department of Physical Sciences, Rhode Island College, USA.
- Office of Immunization, Center for Preventive Services, Division of Community Health and Equity, Rhode Island Department of Health, USA.
- COVID-19 Quant Team, Rhode Island Department of Health, USA.
- Professor of the Practice, School of Data Science & Society, University of North Carolina at Chapel Hill, North Carolina, USA.
Förderung
- State of Rhode Island Department of Health
Zitieren
APA
Motta, M., Callaghan, T., Padmanabhan, M., Ross, J., Gargano, L. M., Bowman, S., & Yokum, D. (2025). Quantifying the prevalence and determinants of respiratory syncytial virus (RSV) vaccine hesitancy in US adults aged 60 or older. Public Health. https://doi.org/10.1016/j.puhe.2024.08.004
Vancouver
Motta M, Callaghan T, Padmanabhan M, Ross J, Gargano LM, Bowman S, et al. Quantifying the prevalence and determinants of respiratory syncytial virus (RSV) vaccine hesitancy in US adults aged 60 or older. Public Health. 2025. doi:10.1016/j.puhe.2024.08.004
BibTeX
@article{Motta2025,
author = {Motta, M and Callaghan, T and Padmanabhan, M and Ross, J and Gargano, L M and Bowman, S and Yokum, D},
title = {Quantifying the prevalence and determinants of respiratory syncytial virus (RSV) vaccine hesitancy in US adults aged 60 or older},
journal = {Public Health},
year = {2025},
doi = {10.1016/j.puhe.2024.08.004}
}
EUVIMED